Skip to main content
TipRanks
Go Ultimate75% OFF

Starpharma Holdings Limited (PQ6) Stock Price & Analysis

0 Followers

PQ6 Stock Chart & Stats

€0.25€0.00(0.00%)
At close: 5:30 PM GMT+1
€0.3€0.4€0.5Aug 6Sep 10Oct 22Oct 29
Day’s Range
EUR 0.25 - EUR 0.25
52-Week Range
EUR 0.16 - EUR 0.52
Previous Close
EUR 0.25
Volume
N/A
Average Volume (3M)
343
Market Cap
EUR 126.06M
Enterprise Value
EUR 284.34M
Total Cash (Recent Filing)
EUR 11.02M
Total Debt (Recent Filing)
EUR 707.00K
Price to Earnings (P/E)
―
Beta
1.39
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Dendrimer Platform

Starpharma’s dendrimer platform supports multiple human-health applications, including pharmaceuticals, topical products and licensed formulations. This provides a reusable technology base that can support several commercial opportunities and diversify development efforts over the medium term.

Debt Reduction

The sharp reduction in debt materially lowers leverage and associated financial risk, giving Starpharma a more conservative capital structure. Lower obligations can preserve cash for research, product development and commercialisation while reducing pressure from interest and refinancing requirements.

Improved Cash Burn

Although cash flow remains negative, the marked improvement in 2026 indicates progress in controlling cash consumption. A lower burn rate can extend the company’s funding runway and provide greater flexibility to pursue its dendrimer pipeline while management works toward profitability.

Bears Say

Persistent Operating Losses

Continued operating and net losses show that Starpharma has not yet converted its technology and products into a profitable operating model. Ongoing losses can constrain reinvestment, increase reliance on external funding and delay the point at which growth translates into durable shareholder returns.

Negative Free Cash Flow

Persistent negative operating and free cash flow means the business continues to consume cash rather than finance operations internally. Unless profitability improves, recurring outflows may require additional funding and could limit the pace of research, development and commercial expansion.

Eroding Equity Base

The substantial decline in equity reflects the cumulative effect of losses and cash burn, leaving Starpharma with a smaller financial resource base than earlier years. This reduces balance-sheet flexibility and makes future investment or funding decisions more consequential if losses persist.

Starpharma Holdings Limited News

PQ6 FAQ

What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest stock price was €0.16 and its highest was €0.52 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is €126.06M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Aug 25, 2026. The company reported -€0.012 earnings per share for the quarter.
Is Starpharma Holdings Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 482,911,040 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of -€0.012 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in DE:PQ6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology